Vernalis Pain Candidate Fails Phase II Trial
This article was originally published in Scrip
Executive Summary
With the failure of Vernalis's lead product candidate from its CNS development portfolio, the UK firm is ending all investment in its new chemical entity (NCE) pipeline and is turning its focus fully towards the upcoming US launch of its extended-release codeine-based cough cold product Tuzistra XR.